On March 14, 2023 Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, reported that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida (Press release, Flare Therapeutics, MAR 14, 2023, View Source [SID1234628730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details are as follows:

Abstract Title: Discovery of FX-909, a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor, to treat patients with the luminal subtype of advanced urothelial cancer (UC)
Session Category: Drug Development Track Special Session
Session Title: New Drugs on the Horizon: Part 2
Presenter: Robert Sims, Ph.D., Chief Scientific Officer and Co-founder of Flare
Date/Time: Sunday, April 16, 2023 from 3:00 to 4:30 p.m. ET
Location: Tangerine Ballroom 2, Convention Center

Flare is advancing FX-909 into the clinic in patients with advanced urothelial cancer (UC). FX-909 is a potent, selective, small molecule inhibitor of the PPARG lineage transcription factor. In pre-clinical models, FX-909 displays meaningful PPARG target gene silencing in UC cell lines as well as tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.